Skip to main content

Innoviva, Inc. (INVA)

NASDAQ: INVA · IEX Real-Time Price · USD
16.16 -0.31 (-1.88%)
Sep 24, 2021 12:59 PM EDT - Market open
Market Cap1.15B
Revenue (ttm)365.49M
Net Income (ttm)265.19M
Shares Out88.42M
EPS (ttm)2.45
PE Ratio6.61
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume116,800
Open16.48
Previous Close16.47
Day's Range16.11 - 16.51
52-Week Range9.21 - 16.73
Beta0.55
AnalystsStrong Sell
Price Target10.00 (-38.1%)
Est. Earnings DateOct 27, 2021

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic ant...

IndustryPharmaceuticals
IPO DateOct 5, 2004
CEOGeoffrey Hulme
Employees5
Stock ExchangeNASDAQ
Ticker SymbolINVA
Full Company Profile

Financial Performance

In 2020, Innoviva, Inc.'s revenue was $336.79 million, an increase of 29.03% compared to the previous year's $261.02 million. Earnings were $224.40 million, an increase of 42.67%.

Financial Statements

Analyst Forecast

According to one analyst, the rating for Innoviva, Inc. stock is "Strong Sell" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
(-38.12% downside)
Analyst Consensus: Strong Sell

News

Innoviva Reports Second Quarter 2021 Financial Results

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the second quarter ended June 30, 2021. Gross royalty revenues of $...

1 month ago - Business Wire

4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

Other symbols:BIIBSAGESIGA
3 months ago - InvestorPlace

GSK Exits Respiratory Partner Innoviva In $392M Deal

GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392 million, at a 3% discount or $12.25 per share. In...

Other symbols:GSK
4 months ago - Benzinga

Innoviva Announces Strategic Repurchase of GSK's Equity Stake

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today announced the execution of definitive agreement to purchase of GSK's equity stake in Innoviva, con...

4 months ago - Business Wire

A Trio of Magic Formula Stock Picks

If you want to increase your chances of beating the market, one method is to pick stocks that rank highly according to the "Magic Formula" criteria.

Other symbols:TUPWSTG
4 months ago - GuruFocus

Innoviva Reports First Quarter 2021 Financial Results

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ:INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2021. Gross royalty revenues of $8...

4 months ago - Business Wire

The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

6 months ago - Benzinga

Top Stocks To Buy Today As Markets Anxiously Anticipate Fed Meeting

The Dow slipped 0.1%, the S&P 500 rose 0.1%, and the Nasdaq climbed 0.6%. In the meantime, Q.ai's Artificial Intelligence has brought out today's top buys.

Other symbols:AAWWCBTGOLFKWR
6 months ago - Forbes

Moving Average Crossover Alert: Innoviva

Innoviva (INVA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

6 months ago - Zacks Investment Research

Innoviva: Q4 Earnings Insights

Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat th...

7 months ago - Benzinga

Innoviva Reports Fourth Quarter 2020 Financial Results

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020. Gross royalty revenues of $93.9 million ...

7 months ago - Business Wire

What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

7 months ago - Zacks Investment Research

Innoviva (INVA) Gains As Market Dips: What You Should Know

In the latest trading session, Innoviva (INVA) closed at $12.51, marking a +1.71% move from the previous day.

7 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for January 5th

Top Ranked Value Stocks to Buy for January 5th

Other symbols:CUBIPAGPSWBI
8 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for January 4th

Top Ranked Value Stocks to Buy for January 4th

Other symbols:DACODP
8 months ago - Zacks Investment Research

Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

8 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 29th

Top Ranked Value Stocks to Buy for December 29th

Other symbols:ODP
8 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 28th

Top Ranked Value Stocks to Buy for December 28th

Other symbols:AMRK
8 months ago - Zacks Investment Research

Combat the Choppy Market With These 5 Low-Beta Stocks

To combat market volatility, create a portfolio of low-beta stocks.

Other symbols:CWTOMIVSTO
8 months ago - Zacks Investment Research

Top Ranked Value Stocks to Buy for December 24th

Top Ranked Value Stocks to Buy for December 24th

Other symbols:CLW
9 months ago - Zacks Investment Research

Innoviva Can Offer 25% Upside From Current Levels

We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near $12 currently and it is, in fact, down 17% from its...

9 months ago - Forbes

Is Innoviva (INVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

9 months ago - Zacks Investment Research

Top Biotech Stocks for Q1 2021

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

9 months ago - Investopedia

Top Ranked Value Stocks to Buy for December 7th

Top Ranked Value Stocks to Buy for December 7th

Other symbols:CPLPQFIN
9 months ago - Zacks Investment Research